Boston Scientific expects to nearly double Target Therapeutics revenues in 1997, CFO says.
This article was originally published in The Gray Sheet
Executive Summary
BOSTON SCIENTIFIC TO NEARLY DOUBLE TARGET THERAPEUTICS REVENUE to "over $170 mil." in 1997, Chief Financial Officer Larry Best predicted June 17 at the Piper Jaffray investment conference in Minneapolis. BSC expects that its newly acquired minimally invasive neurointerventional division, which generated an estimated $89.2 mil. in sales during fiscal year 1997 (ended March 31) as an independent company, will benefit from an ongoing switch to direct sales in international markets.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.